



Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

10/80, Rajendra Gunj, RAICHUR - 584 102. (INDIA)
Phone : 0091-8532-235006, 235704, , FAX : 0091-8532-235876,
E-Mail : info@vbsilpa.com, Website : www.vbsilpa.com

UNAUDITED FINANCIAL RESULTS FOR 3 MONTHS ENDED 30.6.2008 (Rs. / Lakhs)

Sl. No.	Particulars	1st Quarter ended 30.06.2008 (Unaudited)	Corresponding 1st Quarter of the Previous Year 30.06.2007 (Unaudited) *	Consolidated Results as on 30.6.2008 (Unaudited)	Figures for the year ended on 31.3.2008 (Audited)	Consolidated Results for the year ended on 31.3.2008 (Audited)
1	Net Sales / Income from Operations	3040.79	1757.77	3949.44	9581.28	9581.28
2	Other Incomes	45.98	59.41	54.12	252.01	252.01
3	Total Expenditure					
	a. (Increase) / Decrease in the stock in trade	(17.81)	(22.31)	(25.95)	43.78	43.78
	b. Material Cost	1981.76	1171.06	2296.40	6526.37	6526.37
	c. Staff Cost	122.98	47.22	586.12	427.56	427.56
	d. Other Expenditure	217.06	196.27	372.73	718.84	723.66
4	Interest	122.91	10.64	139.86	85.01	85.24
5	Depreciation	138.01	70.95	203.79	351.09	351.09
6	Profit/(Loss) before Extra Ordinary Provisions [1+2-3-4-5]	521.86	343.35	430.61	1680.64	1675.59
7	Less: Extra Ordinary Provision					
	Exchange Fluctuation on ECB	285.00	0.00	285.00	0.00	0.00
8	Profit [+] / Loss [-] before tax[6-7]	236.86	343.35	145.61	1680.64	1675.59
9	Provision for Taxation					
	a. Current Income Tax	125.48	20.00	124.80	320.50	320.50
	b. Deferred Tax	10.10	67.68	9.42	221.02	221.02
	c. Fringe Benefit Tax	0.55	0.42	0.55	2.10	2.10
	Total Provision	136.13	88.10	134.77	543.62	543.62
10	Net Profit [+] / Loss [-] [8-9]	100.73	255.25	10.84	1137.02	1131.97
11	Paid up Equity Share Capital	**440.48	347.15	440.48	425.48	425.48
12	Reserves (as per Balance Sheet) of Previous accounting year to be given in col [5]	-	-	-	5111.71	5105.94
13	Basic & diluted EPS for the period for the year to date & for the Previous year (not to be annualized) Face Value Rs.2/-	0.46	1.47	0.05	5.34	5.32
14	Aggregate of non promoter shareholding					
	No of Shares	8,738,750	1747750	8,738,750	8,738,750	8,738,750
	Percentage of share holding (%)	39.68	50.35	39.68	41.08	41.08

Notes :

- 1) The Company has acquired 99.99% shares of LOBA FEINCHEMIE an Austrian Company having USFDA. This will enable Shilpa to enter European, US, Japan, Australian & other markets, which will go a long way to boost bottom and top line of the Company.
- 2) The above results were reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 29.07.2008.
- 3) Shareholders complaints outstanding at the beginning of the quarter -Nil, received and resolved during the quarter-19, Complaints outstanding at the end of the quarter -Nil.
- *4) Figures for the Corresponding 1st Quarter of the Previous year ended 30.06.2007 are that of Shilpa Medicare Ltd. (before merger) and therefore are not comparable.
- 5) Company has commenced partial production at 100% EOU from March 2008.
- **6) Share Capital increased by Rs.15.00 Lakhs on allotment of shares to warrant holders @ Rs.80/- per share during the quarter.

By the Order of the Board of Directors
M/s. Shilpa Medicare Limited

Omprakash Innani
Chairman

Place: RAICHUR
Date : 29.07.2008



Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

10/80, Rajendra Gunj, RAICHUR - 584 102. (INDIA)

Phone : 0091-8532-235006, 235704, , FAX : 0091-8532-235876,

E-Mail : info@vbsilpa.com, Website : www.vbsilpa.com

UNAUDITED FINANCIAL RESULTS FOR 3 MONTHS ENDED 30.6.2008


Segment wise Revenue, Results and Capital Employed,

under Clause 41 of the Listing Agreement

	Rs. In Lakhs		
	1st Quarter ended 30.06.2008 (Unaudited)	Corresponding 1st Qtr in the Previous year 30.06.2007 (Unaudited)	Previous accounting year ended 31.3.2008 (Audited)
	(1)	(2)	(3)
1. Segment Revenue (net sale/income from each segment should be disclosed under this head)			
a) Bulk Drugs & Intermediates	2962.57	1699.55	9338.00
b) Power	78.22	58.22	243.28
Net sales/income from operation	3040.79	1757.77	9581.28
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment			
a) Bulk Drugs & Intermediates	618.05	347.81	1733.55
b) Power	26.72	6.18	32.10
Total	644.77	353.99	1765.65
Less:			
i. Interest	122.91	10.64	85.01
ii Other un-allocable expenditure net off un-allocable income	-	-	-
Total Profit before Tax & Extra Ordinary provision for exchange fluctuation	521.86	343.35	1680.64
3. Capital Employed (Segment assets-segment liabilities)			
a) Bulk Drugs & Intermediates	*9461.18	4112.61	*8280.51
b) Power	1399.13	1433.34	1396.32
Total	10860.31	5545.95	9676.83

*Above Figures includes the amount capitalised pertaining to 100% EOU recently commissioned, hence capital employed is more.

By the order of the Board of Directors
M/s. Shilpa Medicare Limited.,


Omprakash Innani
Chairman

Place: RAICHUR
Date : 29.07.2008